Additional file 3 of Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study

Additional file 3: Supplementary figure S2. Severe irAEs and efficacy. Kaplan–Meier curves for progression-free survival in patients with irAEs of grade 3 or higher versus patients without irAEs

Additional file 1 of Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study

Additional file 1: Supplementary Table S1. Univariable and multivariable time-varying Cox model analysis of covariates for progression-free survival in the combination therapy and monotherapy groups

Additional file 2 of Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study

Additional file 2: Supplementary figure S1. IrAEs and survival. Kaplan–Meier curves for overall survival in patients treated with pembrolizumab and chemotherapy (a) and those treated with pembrolizumab monotherapy (b)

Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System

<div><p>Background</p><p>Epithelial cell adhesion molecule (EpCAM)-based enumeration of circulating tumor cells (CTC) has prognostic value in patients with solid tumors, such as advanced breast, colon, and prostate cancer. However, poor sensitivity has been reported for non-small cell lung cancer (NSCLC). To address this problem, we developed a microcavity array (MCA) system integrated with a miniaturized device for CTC isolation without relying on EpCAM expression. Here, we report the results of a clinical study on CTCs of advanced lung cancer patients in which we compared the MCA system with the CellSearch system, which employs the conventional EpCAM-based method.</p><p>Methods</p><p>Paired peripheral blood samples were collected from 43 metastatic lung cancer patients to enumerate CTCs using the CellSearch system according to the manufacturer’s protocol and the MCA system by immunolabeling and cytomorphological analysis. The presence of CTCs was assessed blindly and independently by both systems.</p><p>Results</p><p>CTCs were detected in 17 of 22 NSCLC patients using the MCA system versus 7 of 22 patients using the CellSearch system. On the other hand, CTCs were detected in 20 of 21 small cell lung cancer (SCLC) patients using the MCA system versus 12 of 21 patients using the CellSearch system. Significantly more CTCs in NSCLC patients were detected by the MCA system (median 13, range 0–291 cells/7.5 mL) than by the CellSearch system (median 0, range 0–37 cells/7.5 ml) demonstrating statistical superiority (p = 0.0015). Statistical significance was not reached in SCLC though the trend favoring the MCA system over the CellSearch system was observed (p = 0.2888). The MCA system also isolated CTC clusters from patients who had been identified as CTC negative using the CellSearch system.</p><p>Conclusions</p><p>The MCA system has a potential to isolate significantly more CTCs and CTC clusters in advanced lung cancer patients compared to the CellSearch system.</p></div

CTC recovery efficiency and average cell diameter.

<p>Cells were spiked into 1 mL of normal blood and recovered using the MCA system.</p

Gallery of CTCs captured on a transparent MCA from SCLC patient blood.

<p>May-Grünwald–Giemsa-stained cells showed a high nucleus–cytoplasm ratio and nuclear molding (×40). Black arrow indicates 9-µm microcavity. Scale bar = 60 µm.</p

Gallery of cells captured on the MCA from blood of advanced lung cancer patients.

<p>Cells were stained with Hoechst 33342, FITC-labeled anti-cytokeratin antibody, and PE-labeled anti-CD45 antibody.</p

CTC count using the MCA system.

<p>CTC count/7.5 mL blood is shown for 6 healthy donors, 22 NSCLC patients and 20 SCLC patients.</p

Patient characteristics.

<p>Patient characteristics.</p

MCA system for size-based isolation of CTCs.

<p>(a) Schematic diagram of the structure of the MCA system. (b) Scanning electron microscope image of a cultured tumor cell line trapped on the MCA system. (c–f) Cells isolated from SCLC patient blood stained with Hoechst 33342 (c) and fluorescent-labeled antibodies that target cytokeratin (d) and CD45 (e). Merging of the images (f) allowed for identification of CTCs and hematologic cells. Scale bar = 60 µm.</p